Improving patient convenience and substantially reducing dissociative effects of ketamine for the treatment of TRD

The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma in Switzerland comprises an oral prolonged-release formulation of ketamine for Treatment-Resistant Depression (TRD).

The pharmacokinetic profile of this prolonged release formulation could significantly improve the tolerability and patient convenience, by minimizing dissociative effects compared with the currently applied intravenous and intranasal therapies.

TRD patients with insufficient response to standard antidepressants represent 30% of all patients suffering from Major Depressive Disorder (MDD). In this group, our oral prolonged-release formulation of ketamine has shown good response rates.

HMNC Brain Health is also advancing its investigational oral prolonged-release formulation of ketamine for the treatment of TRD with a clinical Phase-II study .

If you'd like to learn more about KET01 and how we're working to make it available to patients, please visit our website at www.ketabon.health There you can find more information about this promising treatment option.